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Abstract
Ventilatory acclimatization to hypoxia is a time-dependent increase in ventilation and the
hypoxic ventilatory response (HVR) that involves neural plasticity in both carotid body che-
moreceptors and brainstem respiratory centers. The mechanisms of such plasticity are not
completely understood but recent animal studies show it can be blocked by administering
ibuprofen, a nonsteroidal anti-inflammatory drug, during chronic hypoxia. We tested the
hypothesis that ibuprofen would also block the increase in HVR with chronic hypoxia in
humans in 15 healthy men and women using a double-blind, placebo controlled, cross-over
trial. The isocapnic HVR was measured with standard methods in subjects treated with ibu-
profen (400mg every 8 hrs) or placebo for 48 hours at sea level and 48 hours at high altitude
(3,800 m). Subjects returned to sea level for at least 30 days prior to repeating the protocol
with the opposite treatment. Ibuprofen significantly decreased the HVR after acclimatization
to high altitude compared to placebo but it did not affect ventilation or arterial O2 saturation
breathing ambient air at high altitude. Hence, compensatory responses prevent hypoventi-
lation with decreased isocapnic ventilatory O2-sensitivity from ibuprofen at this altitude. The
effect of ibuprofen to decrease the HVR in humans provides the first experimental evidence
that a signaling mechanism described for ventilatory acclimatization to hypoxia in animal
models also occurs in people. This establishes a foundation for the future experiments to
test the potential role of different mechanisms for neural plasticity and ventilatory acclimati-
zation in humans with chronic hypoxemia from lung disease.
Introduction
The body’s first line of defense with decreased oxygen levels is the hypoxic ventilatory response
(HVR), which is a reflex increase in breathing in response to low arterial partial pressure of
oxygen (PO2) stimulating carotid body (arterial) chemoreceptors [1]. If hypoxia is sustained,
there is a time-dependent increase in both ventilation and the ventilatory sensitivity to acute
changes in O2 (i.e. the HVR), which collectively are termed “ventilatory acclimatization to
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hypoxia, or VAH” [1,2]. VAH is observed as early as 24 to 48 hours after ascent to high altitude
in healthy humans and persists for at least 8 weeks at an altitude of 3,800m [3–6]. VAH is gen-
erally thought to be advantageous because it can increase arterial O2 levels over time at a given
altitude [1, 2]. This could be beneficial for patients with chronic hypoxemia from lung disease
but it is is not clear if VAH occurs in such patients, or if individual variation in VAH contrib-
utes to differences in the progression of lung disease. Hence, there is an interest in determining
the mechanisms of VAH in humans.
The physiological mechanisms of VAH are not completely understood but considerable
progress has been made in animal studies [1]. Sustained hypoxia increases the isocapnic HVR
by increasing both carotid body chemoreceptor O2-sensitivity, and the “central nervous system
gain of the HVR”, which is an increase in ventilatory motor output for a given afferent input
from carotid body chemoreceptors to respiratory centers in brain [7,8]. The cellular basis for
these changes in animal models is summarized in the Discussion but this study is focused on
the molecular signals for such plasticity, which appear to depend on inflammation. Chronic
hypoxia increases cytokine gene expression and O2-sensitivity in carotid bodies of rats and
these changes are blocked by ibuprofen, a non-steroidal anti-inflammatory drug (NSAID) [9].
Ibuprofen administered during chronic hypoxia also blocks VAH in rats [10]. Considering that
ibuprofen is a generally safe over-the-counter NSAID, and that it is commonly used by people
in sustained hypoxia to alleviate headache from acute mountain sickness, we decided to test the
effects of ibuprofen on VAH in healthy humans. Our goal was to determine if NSAID-sensitive
signals for VAH described for animal models also apply to people.
Materials and Methods
Study Design
We tested the hypothesis that ibuprofen blocks the increase in HVR from chronic hypoxia in
healthy humans using a double-blind, placebo controlled, cross-over trial. This study was
approved by The UCSD Human Subjects Protection Program. Subjects were recruited by flyers
and word of mouth and provided informed written consent. The isocapnic HVR was chosen as
the primary outcome because it is the accepted physiological measure of the mechanisms that
are sensitive to ibuprofen in the animal experiments that inspired this study, namely O2-sensi-
tivity of carotid body chemoreceptors and ventilation. Because the isocapnic HVR can vary in
an individual over time [11, 12] (for example during the month we used to insure there were
no effects of sustained hypoxia between treatments), we compared the effect of high altitude
against a sea level measurement collected with each treatment.
We used the same cohort of subjects in a repeated measures design to improve statistical
power. Subjects were randomized to two groups with crossover; one group (n = 7) took placebo
capsules during the first half of the study and ibuprofen capsules during the second half, and
vice versa for the other group (n = 8). Ibuprofen was administered in the standard over-the-
counter dosage of 400 mg every 8 hours. Placebo treatment used identical capsules (#12 caps)
with lactose fill. The University of California, San Diego Medical Center Investigational Drug
Service prepared both treatments and randomized the treatment order. Treatment order was
blind to investigators performing the experiments but known by a physician involved in the
experimental design and analysis but not data collection. For each half of the study, subjects
were instructed to take the study pill three times per day for two days at sea level and at altitude,
with measurements of their HVR made 24 and 48 hours after starting drug or placebo treat-
ment. Investigators insured that subjects had their pills available at the appropriate starting
time and checked that subjects took their pills during the measurements at high altitude where
they were in residence together. However, drug levels were not verified with blood sampling.
Ibuprofen Blunts Acclimatization to Hypoxia
PLOS ONE | DOI:10.1371/journal.pone.0146087 January 4, 2016 2 / 10
Sea level measurements were performed at the University of California, San Diego and high
altitude measurements were performed in the Pace Laboratory at the Barcroft Facilities of the
White Mountain Research Station (3,800m above sea level, PO2 = 90 Torr). We acclimatized
subjects for 48 hrs because most of the increase in the isocapnic HVR happening over 2 months
at this altitude occurs by this time [4–6]; we studied 24 hrs also to obtain more data and test for
time-dependent effects of ibuprofen at sea level. After completion of the first half of the study,
subjects returned to sea level for one month to insure deacclimatization. The protocol was then
repeated with measurements at sea level and at altitude, with each subject taking the other
study pill.
The data for this study was collected over three summers because of logistical constraints
working at the high altitude laboratory, which is only open during summer months, and chal-
lenges in recruiting subjects who could be away from work or school for several days at a time
in successive months. However, the additional statistical power of the repeated measures design
outweighed these challenges. At the end of the first year, after all of the data had been analyzed
and validated, we un-blinded the treatment to test for effects of ibuprofen on altitude
responses. Results from these 5 subjects showed a trend for ibuprofen to reduce the effect of
altitude to increase the HVR and power calculations based on the observed variability indicated
we would need to study 22 subjects to demonstrate significance. After 3 years, we had collected
complete data on 15 subjects but the cross-over design was randomized evenly in these subjects
and we found a significant effect (see Results) so we ended the study.
Subjects
Complete data sets were obtained for 9 males and 6 females between the ages of 18 and 26
years (average = 24), with a body mass ranging from 45.3 to 94.3 kg, average 63.0 ± 12.3 kg SD.
A medical history was taken and a physical examination performed with special reference to
the cardiopulmonary system to insure subjects were free of cardiovascular or respiratory dis-
ease and had no history of allergies to NSAIDs.
HVR protocol
We used a protocol we have developed over several years for measuring the steady state, iso-
capnic HVR, which is generally accepted as a reflex measurement of the hypoxic sensitivity of
carotid bodies and ventilation [1]. Our method [6] is as a modification of protocols used by the
Severinghaus laboratory [4, 5], which was designed to quantify the isocapnic HVR at different
points in time during sustained hypoxia and account hypoxic ventilatory decline (HVD). HVD
is defined as the decrease in ventilation that starts to occur in the first minutes of sustained
hypoxia [2]. HVD is primarily a decrease in ventilation without a change in the ventilatory O2-
sensivity, although there is evidence for some decrease in ventilatory O2-sensitivity over the
first few minutes of hypoxia [13].
Our protocol has been described in detail before [6, 13]. Subjects underwent a screening ses-
sion one week prior to the first experiment to familiarize them with breathing through the
mask and to insure they had no adverse responses to hypoxia. An EKG was measured to insure
that subjects had no arrhythmias or other abnormal cardiac changes during acute hypoxia. The
time on the breathing apparatus (ca. 30 min) was less than during the full protocol and typi-
cally this screening was completed on the same day as taking a history and making physical
exam.
For experimental sessions, subjects were seated in a semi-recumbent position listening to
music of their choice and breathed through a face mask (Hans Rudolph, Model 7450 V2) con-
nected to a partial rebreathing circuit, which facilitated control of end-expired PCO2 (PE’CO2)
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while changing inspired O2 levels [4]. A three-way valve directed either room air or a mixture
of O2/N2/CO2 (Matheson Tri-Gas, MFMR-1138-SA) to the inspiratory port of a non-rebreath-
ing valve (Hans Rudolph, 2700 2WNRBV). Subjects started breathing room air for 5 minutes
to become comfortable on the equipment, as evidenced by a regular breathing pattern and sta-
ble PE'CO2 (± 2 Torr). Then we switched the three-way valve and subjects started breathing gas
mixtures administered in the rebreathing circuit. Subjects breathed a mild hyperoxic gas mix-
ture (PIO2 210mmHg, equivalent to 30% O2 at sea level) for 15 minutes to raise SaO2 to 100%
at both sea level and altitude, and to reverse any potential HVD that can occur with ambient
hypoxia at high altitude [4].
Next we established the isocapnic end-expired PCO2 level to be maintained throughout
HVR measurements (iPE’CO2) by increasing inspired CO2 until PE’CO2 was 2–3 Torr above the
hyperoxic level. This will slightly increase the isocapnic HVR by the well-known multiplicative
interaction between O2 and CO2 as carotid body stimuli, but more importantly it allows us to
maintain isocapnia even if HVD should decrease ventilation, and increase PE’CO2 during the
protocol [4]. These conditions were maintained for 5 minutes and then we rapidly deceased
inspired O2 until SaO2 reached a target value of 90% and maintained this level for 5 minutes.
The measured change in ventilation between SaO2 = 100% and 90% quantified the acute HVR
without any HVD. We termed this HVR1 as the first measurement of ventilatory O2-sensitivity
in the protocol, which was expressed as the increase in _VI per percent decrease in SaO2 [1, 14].
Then we quantified changes in the HVR with HVD by measuring the HVR during two addi-
tional steps to deeper hypoxia (SaO2 = 80%) at 8 and 14 minutes after the first decrease in SaO2
to 90%. These deeper bouts of hypoxia lasted only 3 min and the change in ventilation between
SaO2 = 90% and 80% was used to calculate an HVR2 and HVR3, as the second and third mea-
surements of HVR in our protocol [6, 13].
Finally, after finishing HVR measurements, subjects returned to breathing PIO2 210 Torr
for 10 minutes to recover from the hypoxia. Then we measured the hypercapnic ventilatory
response (HCVR) by increasing PE’CO2 6 to 10 Torr above the newly measured PE’CO2 value for
6 min [4]. HCVR was expressed as the increase in _VI per Torr increase in PE’CO2.
Physiological Measurements
The primary physiological variables were inspired ventilation ( _VI) measured with a pheumota-
chograph (Fleisch #3) coupled to a differential pressure transducer (Validyne, MP45 ±2
cmH2O) and arterial O2 saturation (SaO2) monitored continuously with a forehead sensor con-
nected to a pulse oximeter (Nellcor, N395), which has been validated against arterial blood in
our laboratory [15]. End-expired PO2 and PCO2 were measured in the mouthpiece continuously
with gas analyzers (Beckman OM11 and LB-2). Analog signals for these measurements were
fed to a data acquisition system (BIOPAC Systems, Inc., MP100A) and imported into data
acquisition software (BIOPAC Systems, Inc., AcqKnowledge version 3.9.1.6, build 06292007)
for subsequent analysis of _VI, (LBTPS/min), tidal volume (VT mlBTPS), fR (breaths/min) end-
expired PCO2 (PE’CO2 Torr), estimated arterial O2 saturation (SaO2%) and to calculate the HVR
and HCVR. HVD was calculated as the decrease in _VI predicted for SaO2 = 85% between
HVR2 and HVR 3 measurements (8 and 14 minutes after the start of hypoxia).
Statistical Analysis
We used ANOVA for repeated measures (Statview, 5.0.1 SAS Institute, Cary, NC) to test for
significant effects of (1) drug, 2 levels = placebo, ibuprophen, (2) altitude, 2 levels = sea level,
3800 m, and (3) time, 2 Levels = 24 hrs, 48 hrs. When we found significant main effects or
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interactions, we did post hoc testing with Fisher’s Protected Least Significant Difference. The
null-hypothesis (no effect) was rejected for P< 0.05, using two tailed for effects on HVD one
tailed for variables with known effects on physiological variables (e.g. altitude increases HVR
and decreases SaO2), or to test our hypothesis that drug treatment with ibuprofen decreases the
HVR at altitude. Data are reported as the mean ± standard deviation.
Results
Twenty-four subjects were screened and signed the consent form but six subjects withdrew
from the study because of scheduling conflicts and three subjects did not produce usable data
(one had no measurable or a negative HVR, another became nervous and showed extreme vari-
ability in breathing independent of respiratory stimuli and one exercised too hard during one
of the trips to altitude and became ill). Some of the remaining 15 subjects had symptoms of
acute mountain sickness but no one felt ill enough to withdraw from the study.
Fig 1 shows the effect of ibuprofen versus placebo on the HVR before and after acclimatiza-
tion to high altitude. It plots HVR1 at 48 hrs, which measures ventilatory sensitivity to O2 with
CO2 held constant before there is any hypoxic ventilatory decline. With placebo, HVR1
increased an average of 2.4-fold at altitude relative to sea level but it only increased 1.4-fold
with ibuprofen. ANOVA showed a significant altitude by drug interaction (Table 1). Post hoc
testing showed that although high altitude increased HVR1 significantly with either placebo
(p = 0.0001) or ibuprofen (p = 0.035), the increase in HVR1 was significantly less with ibupro-
fen versus placebo at high altitude (p = 0. 015). HVR1 was not affected by ibuprofen at sea level
(p = 0.22).
Similar effects were observed on HVR2 and HVR3 (Table 1), which measure ventilatory
O2-sensitivity after hypoxic ventilatory decline (HVD) is established during sustained hypoxia
in our protocol. Both HVR2 and HVR3 showed significant altitude by drug interactions
(Table 1) and decreased with ibuprofen at high altitude, similar to the response shown for
HVR1 in Fig 1. There were no significant differences between HVR1, HVR2 and HVR3 in a
given condition so HVD did not affect ventilatory O2-sensitivity, but absolute levels of _VI
decreased with sustained hypoxia during HVR2 and HVR3 measurements. HVD was calcu-
lated as the change in _VI predicted for SaO2 = 85% between HVR2 and HVR3 to measure-
ments, which is the decrease in _VI between 8 and 14 minutes of sustained hypoxia. HVD
Fig 1. Effects of altitude and ibuprofen on the hypoxic ventilatory response (HVR = ΔV

I / ΔSaO2).
Average HVR1 (± SD), which is the initial measure of the acute HVR, is plotted for 48 hrs of treatment with
placebo (Pla, gray bars) or ibuprofen (Ibu, black bars) at sea level and high altitude. There was a significant
effect of altitude (p = 0.001) and altitude by drug interaction (p = 0.03). Post hoc analysis showed all of the
values were significantly different from each other (p < 0.05) except the two sea level values (p = 0.22).
doi:10.1371/journal.pone.0146087.g001
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showed a significant altitude by drug interaction (p = 0.047, Table 1) and post hoc analysis of
the 48 hour HVD points showed significant increases at high altitude with placebo (p = 0.009)
or ibuprofen (p = 0.03) versus placebo at sea level. There was a non-significant trend (p = 0.06)
for ibuprofen to increase HVD at sea level compared to placebo.
Table 1 summarizes the other respiratory variables for sea level and high altitude during
treatment with ibuprofen also. There was a significant effect of altitude on all variables except
_VI, although it tended to be greater at altitude because VT increased while fR was essentially
constant under all conditions (16.8 ± 0.6 breaths/min). SaO2 was about 10% less at high altitude
with placebo or ibuprofen. Hence, there was no significant altitude by drug interaction for _VI
or SaO2, in contrast to the significant effect on the HVR (Table 1). The decrease in isocapnic
ventilatory O2-sensitivity with ibuprofen at high altitude must be offset by other factors that
prevented significant decreases in breathing or arterial oxygenation when PaCO2 was allowed to
change during ambient air breathing at this altitude.
Altitude significantly increased the hypercapnic ventilatory response (HCVR, p = 0.0001)
but there was no effect of ibuprofen (Table 1). HCVR increased 2.4 and 2.9-fold with placebo
and ibuprofen at altitude, respectively and there was no significant drug by altitude interaction
to indicate and difference with ibuprofen (Table 1). PE’CO2 decreased similarly with placebo or
ibuprofen at altitude also (Table 1). Hence, the effect of ibuprofen at high altitude appears spe-
cific to O2-sensitivity.
Discussion
The results support our hypothesis that ibuprofen impairs ventilatory acclimatization to high
altitude in healthy humans, similar to the effect described in animal studies [10]. Specifically,
the isocapnic HVR after acclimatization to high altitude was significantly decreased by ibupro-
fen versus placebo (Fig 1). Hence, the time-dependent increase of the ventilatory response to
changes in O2 at high altitude in humans depends on a physiological mechanism that is sensi-
tive to a non-steroidal anti-inflammatory drug. We used the standard state of the art methods
Table 1. Effects of placebo vs. ibuprofen treatment on ventilatory acclimatization to altitude. Average values (±S.D.) and effects of placebo vs. ibupro-
fen treatment for 2 days on respiratory variables at sea level and altitude. P values are for ANOVA tests of an altitude by drug interaction and significant values
(p < 0.05) indicate the change in a variable between sea level and altitude is significantly different with ibuprofen vs. placebo. All variables except _VI showed
a significant effect of altitude (p < 0.05). SaO2, arterial O2 saturation measured by pulse oximeter breathing ambient air (%); PE’CO2, end-expired PCO2;
iPE’CO2, isocapnic end-expired PCO2; _VI, ventilation breathing ambient air (L/min); HVR1, HVR2 and HVR3, hypoxic ventilatory response measured between
SaO2 = 100% and 90% (L /(min %)); HVD, hypoxic ventilatory decline, see text (L/min); HCVR, hypercapnic ventilatory response (L (min/Torr)).
Placebo Ibuprofen
Sea Level Altitude Sea Level Altitude
Variable P 24 48 24 48 24 48 24 48
SaO2 (%) 0.29 98.8±0.8 99.3±0.8 89.3±3.9 88.8±4.4 99.1±1.4 99.2±0.7 90.1±2.3 88.4±3.1
PE’CO2 (Torr) 0.75 35.6±3.1 34.6±2.6 29.0±2.5 28.8±2.3 36.0±3.0 36.4±3.3 29.7±2.4 30.2±2.2
iPE’CO2 (Torr) 0.08 38.8±2.7 37.7±2.6 33.6±2.2 33.1±1.8 39.1±2.6 40.1±3.0 33.0±3.3 33.3±1.3
_V I (L /min) 0.38 9.79±1.72 9.61±1.87 11.46±4.81 11.84±3.80 11.31±1.58 10.70±2.23 10.49±4.09 11.40±3.29
HVR1 (L/min %) 0.03 0.47±0.50 0.52±0.63 1.11±0.81 1.26±0.82 0.68±0.54 0.64±0.62 1.06±0.065 0.92±0.55
HVR2 (L/min %) 0.005 0.46±0.48 0.50±0.51 0.96±0.69 0.82±0.51 0.66±0.76 0.78±0.91 0.56±0.30 0.82±0.49
HVR3 (L/min %) 0.03 0.28±0.32 0.47±0.36 0.84±0.61 0.74±0.63 0.63±0.65 0.44±0.36 0.88±0.52 0.57±0.39
HVD (L/min) 0.05 1.36±2.52 1.79±3.95 3.77±3.90 4.88±5.69 4.03±6.22 4.42±7.77 2.57±5.95 5.49±4.68
HCVR (L/min Torr) 0.68 0.92±0.46 1.03±0.72 3.12±2.74 2.85±2.13 1.16±0.62 1.04±0.44 3.04±2.43 2.64±1.18
doi:10.1371/journal.pone.0146087.t001
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to demonstrate these effects [1] and controlled for the potential changes in the HVR that can
occur over time within individuals [11, 16] by an experimental design that compared altitude
and sea level responses measured independently with both treatments.
Our results also show that despite effects of ibuprofen on ventilatory O2-sensitivity, other
mechanisms compensate to prevent decreases in breathing and arterial oxygenation during 48
hrs at this altitude. This is similar to previous studies on the effects of ibuprofen as a treatment
for headache with acute mountain sickness (AMS). Gertsch and co-workers [17] found no sig-
nificant difference in SaO2 with ibuprofen versus placebo in 183 subjects who completed their
double-blind, randomized, placebo-controlled trial. This excluded subjects who had to with-
draw for severe AMS, so it is a population similar to that we studied.
Similar _VI and SaO2 with ibuprofen treatment in our study is also consistent with the well-
known multiple elements of ventilatory acclimatization to hypoxia (VAH) with distinct mech-
anisms. Acclimatization to hypoxia increases both (i) the slope of hypoxic ventilatory response
curves ( _VI vs. SaO2) and (ii) the intercept, i.e. _VI when SaO2 = 100%. The latter effect manifests
as persistent hyperventilation when normoxia is restored after sustained hypoxia, and has been
termed “ventilatory deacclimatization to hypoxia” to emphasize it is not simply the “off
response” of VAH but a distinct mechanism [2]. Experiments show that ventilatory O2-sensi-
tivity can change independently of the persistent hyperventilation in normoxia after chronic
hypoxia (cf. [2]). While it is generally accepted that increased ventilatory O2-sensitivity in
VAH results from both increased carotid body O2-sensitivity and sensitivity of central respira-
tory centers to chemoreceptor afferent input, it is not clear if either of these mechanisms can
explain ventilatory deacclimatization hypoxia [18]. However, we note that whatever compensa-
tory effects may be occurring with ibuprofen at high altitude, there could be different effects on
_VI and SaO2 if subjects were exposed to deeper levels of hypoxia. For example, ibuprofen signif-
icantly decreases _VI in rats breathing 10% O2 without isocapnia [10], which is similar to an alti-
tude of 6,000m above sea level.
The fact that we observed similar effects of ibuprofen at altitude on HVR measured after dif-
ferent durations of hypoxia (i.e. HVR1, 2 and 3) suggests that the ibuprofen effect on O2-sensi-
tivity is independent of hypoxic ventilatory decline (HVD). HVD is a decrease in ventilation
during the first minutes of sustained hypoxia and it can occur without a significant decrease
in ventilatory sensitivity to changes in O2, i.e. it is mainly a decrease in the intercept of a plot of
_VI vs. SaO2 without a change in slope [4,13]. However, our data cannot rule out an independent
effect of ibuprofen on HVD. There was a significant altitude by drug interaction for HVD
(p = 0.05) and HVD tended to be greater under all conditions compared to placebo at sea level
(Table 1). High altitude exposure for 48 hrs significantly increased HVD (relative to the 48 hr
sea level placebo value) by 2.7-fold with placebo (p = 0.009) or 3.1-fold with ibuprofen
(p = 0.03). This effect of 48 hrs of acclimatization on HVD is consistent with some studies [5]
but not others [13] so it is difficult to draw any general conclusions. Our data also showed a
nearly significant (p = 0.06) 2.5-fold increase in HVD after 48 hrs of ibuprofen at sea level com-
pared to placebo. The power of our study is insufficient to reliably rule out such a potential
effect of ibuprofen on HVD at sea level and there is no other evidence published about this so
it needs further study.
Finally, the results show that the effects of ibuprofen are specific to O2-sensitivity because
there were no significant effects of the drug on the hypercapnic ventilatory response (HCVR)
(Table 1). End-expired PCO2 values were comparable under different conditions in our experi-
ments (Table 1) so well-known interactions between O2 and CO2-sensitivity for chemorecep-
tors and ventilation [1] cannot explain the observed differences. We did not measure arterial
blood gases in our study but animal studies show no effects of ibuprofen on arterial pH
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independent of any changes in arterial PCO2 [10], so there is no evidence for ibuprofen-depen-
dent effects on pH that could affect ventilation.
Physiological Significance
The primary goal of our study was to determine if a specific physiological mechanism for
ventilatory acclimatization to hypoxia that has been described in animals also occurs in
humans. This mechanism involves neuroimmune signals that are analogous to those
induced in the peripheral nervous system during chronic inflammatory pain, and which
also cause chemoreceptor plasticity [19]. In rats, chronic sustained hypoxia increases the
number of ED1+ immune cells in the carotid body and the expression of mRNA for cyto-
kines; the expression of cytokine genes was not limited to immune cells but also involves
carotid body Type 1 and 2 cells [9]. These changes and the increased hypoxic neural
responses of carotid body chemoreceptors with chronic hypoxia could be blocked by dexa-
methasone or ibuprofen [9]. The ibuprofen dose used for those animal studies (4 mg/kg)
was chosen for its ability to suppress phenotypic changes in rat primary sensory neurons
induced by inflammation [20] and was equivalent to the therapeutic dose for a child. That
same ibuprofen dose also blocks the effect of chronic hypoxia to increase cytokine gene
expression in medullary respiratory centers and ventilatory acclimatization to hypoxia in
rats [10]. In this study, we used a dose of 400 mg, 3 times/day for all subjects, resulting in a
dose of ca. 6 mg/kg 3 times/day, which is at the low end of the therapeutic range for adults
(400–800 mg, 3–4 times/day). As discussed above, ibuprofen is frequently used at such
doses to treat high altitude headache without affecting respiration. The observation that
similar doses of ibuprofen block ventilatory acclimatization to hypoxia in both rats and
humans supports our hypothesis that sustained hypoxia evokes the same mechanism
involving inflammatory signals in both species.
However, questions remain about the exact mechanisms of the ibuprofen on VAH in
humans and answering them will be important to understand if neural plasticity in ventila-
tory control plays a role in patients with chronic hypoxemia. Progress is being made on the
cellular mechanisms and molecular signals for such plasticity in animal studies. These show
that neural plasticity with chronic hypoxia involves plasticity that is sensitive to ibuprofen in
both peripheral arterial (carotid body) chemoreceptors [9] and respiratory centers in the cen-
tral nervous system (CNS) [10]. Cytokines expressed in chronically hypoxic carotid bodies,
which can be blocked by ibuprofen, cause increased gene expression for chemical and voltage
sensitive ion channels that increase O2-sensitivity [19]. Plasticity in CNS respiratory centers
with chronic sustained hypoxia involves changes in glutamatergic neurotransmission, ion
channels that increase synaptic transmission and intrinsic neuronal excitability, and neuron-
glia interactions [21–23]. Glia are an important source of cytokines in neuropathic pain,
which is hypothesized to share common mechanisms with carotid body acclimatization to
hypoxia and is sensitive to ibuprofen [19,24, 25]. Finally, while ibuprofen is a cyclooxygenase
(COX) inhibitor, it may act by mechanisms other than its classic anti inflammatory effect to
reduce prostaglandin formation by inhibiting COX-2 [26]. Ibuprofen can block NF-κB tran-
scription of cytokines independently of its effect to inhibit COX [27]. Also, hypoxia increases
NF-κB both directly via prolyl hydroxylases [28], and indirectly through positive feedback
interactions between NF-κB and hypoxia inducible factor-1α α (HIF-1α) [29–32]. HIF-1α is
neccessary for normal VAH [33] so ibuprofen has the potential to affect VAH via NF-κB
effects on both cytokines and HIF-1α. Further study will be necessary to determine which, if
any, of these cellular mechanisms and molecular signals are involved in VAH in humans in
health or disease.
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